Summary by Moomoo AI
Ming Kand Pharmaceuticals proposes to approve the 2024 H-Share Award Trust Plan at the 2023 Annual General Meeting and authorising the Board and/or the Authorised Persons to handle the relevant matters. The program aims to attract, incentivize and retain talent through corporate equity award opportunities to align corporate pay policies with shareholders' interests. The plan will take effect after approval at the 2023 Annual General Meeting and will last for a period of ten years. The source of the funds is the company's own funds, and the beneficiaries of the plan will purchase H shares through an in-market transaction as directed by the company. The plan is limited to purchase H shares using no more than HK$20. Five executives, including Dr. Li Keung, the expected executive director, may have significant interests in the scheme and will give up voting rights on relevant board resolutions. The Company will send a circular to shareholders in due course detailing its plans and rules for 2024 and will hold its Annual General Meeting in 2023.